- Home
- RDHL vs THAR Comparison
RDHL vs THAR Comparison
Compare RDHL & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- THAR
- Stock Information
- Founded
- RDHL 2009
- THAR 2017
- Country
- RDHL Israel
- THAR United States
- Employees
- RDHL N/A
- THAR N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- THAR Health Care
- Exchange
- RDHL Nasdaq
- THAR Nasdaq
- Market Cap
- RDHL 3.8M
- THAR 3.3M
- IPO Year
- RDHL N/A
- THAR 2022
- Fundamental
- Price
- RDHL $1.85
- THAR $1.82
- Analyst Decision
- RDHL
- THAR Strong Buy
- Analyst Count
- RDHL 0
- THAR 1
- Target Price
- RDHL N/A
- THAR $17.00
- AVG Volume (30 Days)
- RDHL 18.5K
- THAR 41.7K
- Earning Date
- RDHL 04-10-2025
- THAR 08-08-2025
- Dividend Yield
- RDHL N/A
- THAR N/A
- EPS Growth
- RDHL N/A
- THAR N/A
- EPS
- RDHL N/A
- THAR N/A
- Revenue
- RDHL $8,042,999.00
- THAR N/A
- Revenue This Year
- RDHL $381.91
- THAR N/A
- Revenue Next Year
- RDHL N/A
- THAR N/A
- P/E Ratio
- RDHL N/A
- THAR N/A
- Revenue Growth
- RDHL 23.17
- THAR N/A
- 52 Week Low
- RDHL $1.71
- THAR $0.95
- 52 Week High
- RDHL $20.28
- THAR $6.39
- Technical
- Relative Strength Index (RSI)
- RDHL 43.03
- THAR 64.36
- Support Level
- RDHL $1.72
- THAR $1.30
- Resistance Level
- RDHL $2.08
- THAR $1.46
- Average True Range (ATR)
- RDHL 0.09
- THAR 0.14
- MACD
- RDHL 0.01
- THAR 0.02
- Stochastic Oscillator
- RDHL 27.78
- THAR 96.17
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.